XML 75 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Note 16 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Reported Value Measurement [Member]    
Cash and cash equivalents $ 8,440 $ 3,757
Other receivables 349,003 424,110
Note receivable - related party 44,859 44,859
Advances to CEN Biotech Ukraine, LLC - related party 1,065,328 1,065,328
Loans payable 10,107,513 10,121,411
Loans payable – related parties 1,360,845 1,362,600
Patent acquisition liability 720,000 720,000
Convertible notes payable 6,434,445 6,224,325
Convertible notes payable – related parties 2,558,681 2,558,681
Estimate of Fair Value Measurement [Member]    
Cash and cash equivalents 8,440 3,757
Other receivables 349,003 424,110
Note receivable - related party 44,859 44,859
Advances to CEN Biotech Ukraine, LLC - related party 1,065,328 1,065,328
Loans payable 10,107,513 10,121,411
Loans payable – related parties
Patent acquisition liability 720,000 720,000
Convertible notes payable 7,283,393 6,918,486
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents
Other receivables
Note receivable - related party
Advances to CEN Biotech Ukraine, LLC - related party
Loans payable
Loans payable – related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents 8,440 3,757
Other receivables
Note receivable - related party
Advances to CEN Biotech Ukraine, LLC - related party
Loans payable
Loans payable – related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents
Other receivables 349,003 424,110
Note receivable - related party 44,859 44,859
Advances to CEN Biotech Ukraine, LLC - related party 1,065,328 1,065,328
Loans payable 10,107,513 10,121,411
Loans payable – related parties
Patent acquisition liability 720,000 720,000
Convertible notes payable 7,283,393 6,918,486
Convertible notes payable – related parties